REVEALED: Inhibrx biosciences - The Real Truth

Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup

Inhibrx Biosciences' CEO bought $3.6 million in shares after strong Phase 2 data, as insiders accumulate stock amid heavy short interest and an upcoming FDA decision on ozekibart.

MarketBeat · Oct 2

Adding an Experimental OX40 Drug to Keytruda Nearly Doubled Tumor Responses in Advanced Head and Neck Cancer

An experimental OX40 drug plus Keytruda nearly doubled tumor responses in head and neck cancer. The company's data are early and not peer-reviewed.

Medical Daily · Sep 10

Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and dee

MarketBeat · May 11